斯钙素2在喉鳞状细胞癌中的表达及预后的相关性研究

张存良; 关中; 彭解人

doi:10.13201/j.issn.1001-1781.2015.02.002

斯钙素2在喉鳞状细胞癌中的表达及预后的相关性研究

- 1 顺德区第一人民医院耳鼻咽喉科(广东佛山, 528300);
- 2 中山大学孙逸仙纪念医院耳鼻咽喉头颈外科

详细信息

通讯作者: 彭解人,E-mail:18926107606@189.cn

中图分类号: R739.65

收稿日期: 2014-06-23

The correlation between stanniocalcin 2 expression and prognosis in laryngeal squamous cell cancer

- 1 Department of Otorhinolaryngology, the First People's Hospital of Shunde District, Foshan, 528300, China;
- 2 Department of Otorhinolaryngology-Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

More Information

Corresponding author: PENG Jieren, E-mail: 18926107606@189.cn

Received Date: 23 June 2014

摘要

摘要: 目的:本研究通过检测喉癌和癌旁正常组织中斯钙素2(STC2)的表达水平,探讨其与喉癌临床病理相关因素及预后之间的关系。方法:回顾性分析2005-01-2009-03期间收治的81例喉癌病例,癌旁正常标本30例作为对照组。采用免疫组织化学的方法检测喉癌组织和癌旁正常组织中STC2的表达。结果:①STC2在喉癌组中的表达显著高于对照组,2组差异有统计学意义(P<0.05);②喉癌中STC2的表达与肿瘤淋巴结转移、临床分期、T分期、病理分级、肿瘤的部位相关,组间差异有统计学意义P<0.05),而与性别、年龄无明显相关,差异无统计学意义(P>0.05);③在肿瘤表达STC2分组生存分析中,STC2表达阳性的喉癌患者比表达阴性的患者预后差(P<0.05);④喉癌的临床分期作为喉癌预后的预测因子之一(P<0.05),而STC2表达水平不能作为喉癌预后的独立预测因子(P>0.05)。结论:STC2表达水平与喉癌患者累积生存时间呈负相关。
- 斯钙素2 /
- 喉鳞状细胞癌 /
- 预后
Abstract: Objective: In this study, we have detected the expression of STC2 protein in laryngeal cancer and the safe incisal margin by immunohistochemical staining, to evaluate its correlation with clinical features and the prognosis value in laryngeal squamous cell cancer.Method: Eighty-one paraffin-embedd specimens of patients who underwent surgery for laryngeal cancer were collected. Clinical data, including date of birth, gender, tumor subsite, tumor stage, RT, and survival status have been recorded. The samples including laryngeal cancer tissues and the safe incisal margin were analyzed for the expression of STC2 protein by immunohistochemical staining. We analyzed the correlations with STC2 expression level and clinical data with software SPSS 18.0.Result: ①Fifty-six cases in 81 cases(69.1 %)are positive. In 30 cases of the safe incisal margin tissues, STC2 is not expressed, which shows statistically significant differences between the two groups (P<0.05).②Overexpression of STC2 in laryngeal cancer were correlated with the tumor clinical stage and N stage, T stage, tumor site location and histological grade (P<0.05), but not with genderor age (P> 0.05).③The result showed that the 3-year survival rate is 74.1%, according to the survival analysis by STC2, STC2 positive group has poorer outcome versus the negative group.④The clinical stage displayed the independent value in predicting the tumor prognosis of laryngeal cancer (P<0.05), not the expression level of STC2.Conclusion: Overexpression of STC2 in laryngeal cancer patients is correlated with poor outcome, which means STC2 positive group has poorer prognosis than the STC2 negative group.
- STC2 /
- laryngeal squamous cell carcinoma /
- prognosis

HTML全文

参考文献(26)

[1]	JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008,58:71-96.
[2]	BARNES L, LLY T, HUNT J L, et al. Tumours of the hypopharynx, larynx and trachea:introduction[M]//BARNES L, EVESON J W, REICHART P, et al. World Health Organization Classification of Tumours Pathology and Genetics of Head and Neck Tumours. Lyon:IARC Press,2005:111-117.
[3]	HOFFMAN H T, PORTER K, KARNELL L H, et al. Laryngeal cancer in the United States:changes in demographics, patterns of care, and survival[J]. Laryngoscope, 2006,116:1-13.
[4]	ECKEL H E. Endoscopic laser resection of supraglottic carcinoma[J]. Otolaryngol Head Neck Surg, 1997,117:681-687.
[5]	LUTZ C K, JOHNSON J T, WAGNER R L, et al. Supraglottic carcinoma:patterns of recurrence[J]. Ann Otol Rhinol Laryngol, 1990,99:12-17.
[6]	ISHIBASHI K, IMAI M. Prospect of a stanniocalcin endocrine/paracrine system in mammals[J].Am J Physiol Renal Physiol, 2002,282:F367-375.
[7]	CHANG A C, JEFFREY K J, TOKUTAKE Y, et al. Human stanniocalcin (STC):genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats[J]. Genomics, 1998,47:393-398.
[8]	ISMAIL R S, BALDWIN RL, FANG J, et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells[J]. Cancer Res, 2000,60:6744-6749.
[9]	OKABE H, SATOH S, KATO T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray:identification of genes involved in viral carcinogenesis and tumor progression[J].Cancer Res, 2001,61:2129-2137.
[10]	WATANABE T, ICHIHARA M, HASHIMOTO M, et al. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation[J]. Am J Pathol, 2002,161:249-256.
[11]	BUCKANOVICH R J, SASAROLI D, O'BRIEN-JENKINS A, et al. Tumor vascular proteins as biomarkers in ovarian cancer[J].J Clin Oncol, 2007,25:852-861.
[12]	JOENSUU K, HEIKKILA P, ANDERSSON LC. Tumor dormancy:elevated expression of stanniocalcins in late relapsing breast cancer[J].Cancer Lett, 2008,265:76-83.
[13]	IETA K, TANAKA F, YOKOBORI T, et al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer[J]. Int J Cancer, 2009,125:926-931.
[14]	MEYER H A, TOLLE A, JUNG M, et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma[J]. Eur Urol, 2009,55:669-678.
[15]	TAMURA K, FURIHATA M, CHUNG S Y, et al. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer[J].Cancer Sci, 2009,100:914-919.
[16]	YOKOBORI T, MIMORI K, ISHII H, et al. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer[J]. Ann Surg Oncol, 2010,17:2601-2607.
[17]	VOLLAND S, KUGLER W, SCHWEIGERER L, et al. Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma[J]. Int J Cancer, 2009,125:2049-2057.
[18]	KITA Y, MIMORI K, IWATSUKI M, et al. STC2:a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma[J]. Ann Surg Oncol, 2011,18:261-272.
[19]	林鹏, 王巍, 蔡文娟, 等. 喉癌组织中缺氧诱导因子1α和表皮生长因子受体的表达与微血管密度的关系[J]. 中华耳鼻咽喉头颈外科杂志, 2009,44(6):480-485.
[20]	MOORE E E, KUESTNER R E, CONKLIN D C, et al. Stanniocalcin 2:characterization of the protein and its localization to human pancreatic alpha cells[J]. Horm Metab Res, 1999,31:406-414.
[21]	YEUNG B H, LAW A Y, WONG C K. Evolution and roles of stanniocalcin[J]. Mol Cell Endocrinol, 2012,349:272-280.
[22]	ZEIGER W, ITO D, SWETLIK C, et al. Stanniocalcin 2 is a negative modulator of store-operated calcium entry[J]. Mol Cell Biol, 2011,31:3710-3722.
[23]	ZHANG S L, YU Y, ROOS J, et al. STIM1 is a Ca²⁺ sensor that activates CRAC channels and migrates from the Ca²⁺ store to the plasma membrane[J]. Nature, 2005,437:902-905.
[24]	LAW A Y, WONG C K. Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells[J]. Exp Cell Res, 2010,316:3425-3434.
[25]	LAW A Y, LAI K P, IP C K, et al. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells[J].Exp Cell Res, 2008,314:1823-1830.
[26]	ITO D, WALKER J R, THOMPSON C S, et al. Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties[J]. Mol Cell Biol, 2004,24:9456-9469.